Clinical Trials
50 trialsNCT06077500 2026-05-27
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06066138 2026-05-22
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07155174 2026-05-18
SEZanne
AbbVie
Phase 2 Recruiting
NCT07472517 2026-05-12
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Recruiting
NCT06646276 2026-05-11
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT07339059 2026-04-23
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT07545954 2026-04-22
DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07226999 2026-04-20
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Pfizer
Phase 2/3 Recruiting
NCT03540420 2026-04-13
ACHILES
Norwegian University of Science and Technology
Phase 2 Active not recruiting
NCT07407933 2026-04-09
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT04919382 2026-04-08
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT04256421 2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT06807632 2026-04-01
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04471727 2026-02-24
MK-6070-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Active not recruiting
NCT06830694 2026-02-23
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Samsung Medical Center
Phase 2 Recruiting
NCT04665856 2026-02-13
SKYSCRAPER-02C
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06712355 2026-02-13
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Phase 3 Recruiting
NCT03830918 2026-02-12
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03782207 2026-01-08
IMreal
Hoffmann-La Roche
Active not recruiting
NCT04373369 2025-11-03
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT03041311 2025-09-25
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
Phase 2 Completed
NCT05652686 2025-09-23
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT05224141 2025-07-08
KEYVIBE-008
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04101357 2025-03-18
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
BioNTech SE
Phase 1/2 Terminated
NCT06663098 2025-03-13
CARRY-ON
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Recruiting
NCT06780826 2025-01-17
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Recruiting
NCT06771518 2025-01-13
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Regina Elena Cancer Institute
Phase 2 Recruiting
NCT04923776 2024-12-30
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Columbia University
Phase 2 Terminated
NCT06719336 2024-12-05
Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)
Peking University Cancer Hospital & Institute
Phase 3 Not yet recruiting
NCT04920981 2024-11-07
CLINATEZO
Intergroupe Francophone de Cancerologie Thoracique
Completed
NCT04622228 2024-07-29
Match
Hoffmann-La Roche
Phase 2 Completed
NCT04028050 2024-07-16
MAURIS
Hoffmann-La Roche
Phase 3 Completed
NCT04730999 2024-07-05
CeLEBrATE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT04487756 2024-04-03
VENEZO-LUNG
Instituto Oncológico Dr Rosell
Phase 1/2 Unknown
NCT04610684 2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04253145 2023-11-18
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
Fundacion Oncosur
Phase 1/2 Unknown
NCT04308785 2023-10-23
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT02763579 2023-07-28
IMpower133
Hoffmann-La Roche
Phase 3 Completed
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT05797493 2023-04-04
PICASSO
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05703997 2023-01-30
FASTIMMUNE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Not yet recruiting
NCT03232593 2022-08-24
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Hoffmann-La Roche
Completed
NCT04422210 2021-11-08
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
Hoffmann-La Roche
Phase 1 Terminated
NCT03059667 2021-02-10
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT04696939 2021-01-06
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT02748889 2018-07-02
Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Georgetown University
Phase 1/2 Terminated